January – June · Revenues amounted to MSEK 1 965.3 (1 460.9), corresponding to an increase of +35% for the period.· The organic growth1 during the period was +6%. The currency impact was +3% while the acquisitions of the Sylphar Group and E45® brand portfolio from Reckitt generated growth of +26%.· EBIT (Operating Profit) amounted...
Not for release, publication or distribution, directly or indirectly, in or into Australia, Hong Kong, Japan, Canada, New Zealand, South Africa, Switzerland, Singapore, the United States or any other jurisdiction in which the distribution or release would be unlawful or require further registration measures. This press release does not constitute an offer of any securities of Karo Pharma Aktiebolag. See the section “Important information” below.
Today, on 12 April 2022, Karo Pharma is publishing its annual report for 2021 on the company’s website, www.karopharma.com. For further information, please contact: Lisa Westerdahl, Head of Corporate Communication, 073-329 70 04, lisa.westerdahl@karopharma.com Jon Johnsson, CFO, 073-507 88 61, jon.johnsson@karopharma.com The Annual Report is published in Swedish and English. The Swedish version represents the...
Karo Pharma Aktiebolag (“Karo”) has today completed the previously announced acquisition of the skin health brand, E45®, from Reckitt for a total consideration of GBP 200m. All conditions to the completion of the transaction have been satisfied.
Not for release, publication or distribution, directly or indirectly, in or into Australia, Hong Kong, Japan, Canada, New Zealand, South Africa, Switzerland, Singapore, the United States or any other jurisdiction in which the distribution or release would be unlawful or require further registration measures. This press release does not constitute an offer of any securities of Karo Pharma Aktiebolag. See the section “Important information” below.
Not for release, publication or distribution, directly or indirectly, in or into Australia, Hong Kong, Japan, Canada, New Zealand, South Africa, Switzerland, Singapore, the United States or any other jurisdiction in which the distribution or release would be unlawful or require further registration measures. This press release does not constitute an offer of any securities of Karo Pharma Aktiebolag. See the section “Important information” below.
Karo Pharma Aktiebolag (publ) (the “Company” or ”Karo Pharma”) announced in a press release on 9 March 2022 that Karo Pharma’s Board of Directors has decided to apply for delisting of the Company’s share from Nasdaq Stockholm as well as listing on Nasdaq Stockholm First North Growth Market, and that the application on delisting had...
The Board of Directors of Karo Pharma Aktiebolag (publ) (the “Company” or “Karo Pharma”) has today decided to apply for and submitted the application regarding delisting of the Company’s shares from Nasdaq Stockholm as well as decided to apply for listing of the Company’s shares on Nasdaq First North Growth Market (the “First North-listing”).
Q4, October – December · Revenues amounted to MSEK 762.0 (721.2), corresponding to an increase of +6% for the period.· The organic growth1 during the fourth quarter was +9%. The currency impact in the quarter was 1% while the acquisitions adjusted for the divestments generated a net effect of -5%.· EBIT (Operating Profit) amounted to...
Karo Pharma Aktiebolag (“Karo”) today announces that the previously announced acquisition of the Belgian fast-growing digital-first brand company Sylphar International NV (“Sylphar”) for EUR 290m has been successfully completed according to plan. The transaction is expected to contribute positively to Karo’s market position and further enhance Karo’s strong platform for continued growth, particularly in the...
